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BACKGROUND: The immunohistochemical features of fetal haemoglobin cells and their distribution patterns in solid tumours, such
as colorectal cancer and blastomas, suggest that fetal haemopoiesis may take place in these tumour tissues. These locally highly
concentrated fetal haemoglobin (HbF) cells may promote tumour growth by providing a more efficient oxygen supply.
METHODS AND RESULTS: Biomarkers of HbF were checked in transitional cell carcinoma (TCC) of the urinary bladder, assessing this as a
new parameter for disease management. Fetal haemoglobin was immunohistochemically examined in tumours from 60 patients with
TCC of the bladder. Fetal haemoglobin erythrocytes and erythroblasts were mainly clonally distributed in proliferating blood vessels
and not mixed with normal haemoglobin erythrocytes. The proportion of such HbF blood vessels could reach more than half of the
total number of vessels. There were often many HbF erythroblasts distributed in one-cell or two-cell capillaries and present as 5–15%
of cells in multi-cell vessels. This suggests a local proliferation of HbF-cell progenitors. Fetal haemoglobin cells were prominently
marking lower grades of tumours, as 76% (n¼ 21) of the patients with G1pTa were HbFþ , whereas only 6.7% (n¼ 30) of the
patients with G3pT1-pT2a were HbFþ .
CONCLUSION: Our results suggest that HbF, besides being a potential new marker for early tumour detection, might be an essential
factor of early tumour development, as in fetal life. Inhibiting HbF upregulation may provide a therapeutic target for the inhibition
of tumour growth.
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Systemic, high, whole blood concentration of fetal haemoglobin
(HbF) is a well-established feature of haematological and solid
tumours (Sheridan et al, 1976; Wolk et al, 1988, 1991, Rautonen
and Mari, 1990). However, there is evidence suggesting local
proliferation of HbF cells in tumour tissues. This was serologically
demonstrated in lymphoma, ovarian cancer, brain cancer and
other cancers by a high plasma HbF concentration independent
of the whole blood concentration (Wolk et al, 1999). The same was
also immunohistochemically shown in colorectal tumours (Wolk
et al, 2006), as well as in blastomas (Wolk et al, 2007), by high
concentrations of HbF erythroid cells, distributed as separated
clusters rather than mixed with the normal erythrocytes, in blood
vessels. To investigate this trait further, we decided to examine
HbF in transitional cell carcinoma (TCC) of the urinary bladder in
relation to the grade and stage of the disease. Although new
markers for TCC have been evaluated during the past decade in
order to improve management, they have not replaced traditional
methods of urine cytology, although this is limited by its low
sensitivity (Mukhtar and Perry, 2011). The most promising of
these new techniques involve specific protein immunoassay
(Stoeber et al, 2002) or molecular (Miyake et al, 2010) and
genomic (Wang et al, 2009) biomarkers and require complicated
techniques, which are not yet compatible with clinical practice.
Fetal haemoglobin, however, if proved a suitable marker for TCC,
might be easily evaluated serologically in blood or urine and
by immunohistochemistry in tumour biopsies.
MATERIALS AND METHODS
Participants
The study was conducted in the Blizard Institute, Core Pathology
Group, Barts and The London School of Medicine and Dentistry,
using archival and stored materials. The study was approved by
the Research Ethics Committee of the East London and City Health
Authority. Histopathological specimens from bladder TCC patients
were selected from the archive of the Department of Histopatho-
logy, the Royal London Hospital. The grade and stage of tumours
were derived from records and reviewed for the blocks studied.
The study comprised 60 patients, of whom 9 were women.
The patients’ age range was 43–97 years (median¼ 76); the grade
distribution was as follows: 21 patients¼G1, 8¼G2, 30¼G3 and
1¼ in situ TCC. Five controls of non-malignant bladder tissues
were examined in parallel. No chemotherapy treatment was given
at least 6 months preceding excision of the specimens.
Immunohistochemical staining
We used the peroxidase-labelled avidin–biotin method (Hsu and
Raine, 1984). Formalin-fixed, paraffin wax-embedded cross-
sections were cut at 3 mm, dewaxed, and then blocked for
endogeneous peroxidase with 3% H2O2 in water for 15min, and
washed for 5min in water and then for 5min in TBS (0.05
tris buffered saline) wash buffer (Dako A/S, Glostrup, Denmark).
The following incubation steps were used: (1) blocking with
normal rabbit serum, diluted 1 : 5 for 30min; (2) incubation with
primary antibody, that is, affinity-purified sheep anti-human HbF
(Abcam, Cambridge, UK), diluted 1 : 400 for 60min; (3) incubation
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with secondary antibody, i.e., biotinylated rabbit anti-sheep IgG
(Vector Laboratories, Burlingame, CA, USA), diluted 1 : 150 for
30min; (4) incubation with ready-to-use streptavidin–biotin
complex (RTU Vectastain Elite ABC, Vector Laboratories) for
30min; and (5) incubation with DAB solution (chromogen; DAB
kit, Vector Laboratories) for 4min. The sections were then washed
for 5min in running water, automatically counterstained with
Gill’s haematoxylin, blue-differentiated, dehydrated and mounted.
Between steps (1) through (4), the sections were washed in TBS
wash buffer for 5min. Staining was confirmed by two controls,
where in step (2) we used the same anti-human HbF absorbed with
HbF as negative control and human HbF absorbed with normal
haemoglobin (HbA) as positive control. Fetal haemoglobin and
HbA were prepared from the corresponding red cell lysates,
insolubilised by the aid of gluteraldehyde (Wolk and Kieselstein,
1983) and then two volumes of anti-HbF were shaken at room
temperature for 12 h, with one volume of either of those
absorbents. The supernatants were then saved for control staining
in place of the primary antibody.
RESULTS
The criteria for positivity were as follows: (1) proliferating
fine vessels with 100% HbF blood cells, distributed throughout
the section; and (2) larger blood vessels with 450% HbF blood
cells. Negative cases were sections without HbF blood cells, or with
occasional o1%–5% HbF blood cells. As shown in Table 1, the
percentage of HbFþ tumours was much higher in the non-
invasive, low-grade G1 group (76%) than in the high-grade G3
group (6.7% ), whereas in the G2 group it was intermediate (50%).
Fetal haemoglobin blood cell distribution is given in Table 2, in
which a distinction is made between three kinds of blood vessels:
(1) with adult haemoglobin (HbA) blood cells, (2) with a mixed
population, including 10–40% HbF cells and (3) with predomi-
nantly HbF blood cells, 450% HbF cells. As shown in this table,
the percentages of HbFþ vessels were, in most cases, over 50%
(Figures 1A–C). Proliferation of HbF cells was indicated by
nucleated (erythroblast and proerythroblast) cells filling one- or
two-cell capillaries (Figure 2) or mixed with the HbF erythrocytes
(Figures 1, 3 and 4). As shown in Table 2, the HbF blood vessels
were distributed within the tumour (Figures 3 and 4) and in the
lamina propria (Figures 1A–C), where the most intensive
proliferation of fine blood vessels was noted. The HbF and the
non-HbF blood vessels were distributed in separated areas
throughout the sections. Proliferation of blood vessels with non-
HbF blood cells, although present in low-grade G1 patients, was
most prominent between the invasive tumour cells of high-grade
G3 patients (Figure 5), where no vessels with HbF cells were
observed.
Five control biopsies from patients suspected of cancer, which
were normal, were all without HbF blood cells.
DISCUSSION
Local proliferation of HbF blood cell progenitors within the
tumour is likely to be the main mechanism responsible for the high
concentration of HbF blood cells. The histological picture shows
multiple nucleated HbF cells (Figure 1, Table 2), sometimes filling
up small capillaries (Figure 2), and proliferative patterns of fine to
Table 1 Ratios of positive HbF (HbFþ ) and negative HbF (HbF )
patients in different grades of TCC (%)
HbFþ HbF
Grade
Total no. of
patients
Stage
distribution
Total no. of
patients
Stage
distribution
pTa 1 1a 2 2a pTa 1 1a 2 2a
G1 16 (76) 16 5 (24) 5
G2 4 (50) 2 2 4 (50) 4
G3 2 (6.7) 1 1 28 (93.3) 14 1 1 12
Abbreviation: TCC¼ transitional cell carcinoma.
Figure 1 Stages in proliferation of blood vessels with HbF cells in lamina
propria of G1 TCC. Arrows indicating nucleated HbF progenitor cells:
(A) clusters of HbF cells forming into fine vessels with many foci of nucleated
HbF progenitor cells. (B) High density of small proliferating blood vessels.
(C) Larger blood vessels spreading throughout the lamina propria.
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bigger blood vessels, filled predominantly with HbF cells apart
from the normal Hb vasculature, probably due to the local fetal
haemopoiesis in the tumour tissue. The extremely high concentra-
tion of blood vessels with HbF cells throughout TCC bladder tissue
makes the bladder erythroid blood supply predominantly a fetal
one. Owing to its high oxygen affinity, HbF might have a particular
role in supporting cancer growth by providing an efficient oxygen
delivery to the cells, as it does in fetal tissues during gestation
(Carlson, 1988; Manca and Masala, 2008). Fetal haemoglobin (HbF)
gene upregulation might thus be an important factor in supporting
low-grade tumours, and it is possible that its inhibition may help
to arrest the malignant process at an early stage. This is relevant to
therapeutic strategies for tumours, aimed at angiogenesis, which is
an important strategy in cancer therapy (Wu et al, 2008; Goel et al,
2011). We therefore suggest that the reduction of HbF cells inside
tumour vasculature, along with inhibiting proliferation of the
unique endothelial cells of the tumour, might be a useful approach.
Despite many studies having been conducted, the molecular
mechanism of HbF regulation is not completely understood.
However, in the silencing of g-genes expression in normal adults,
there is thought to be a fundamental role of DNA methylation
(Lavelle, 2004; Saunthararajah et al, 2004; Sankaran, 2011).
Consequent to methylation, there is induction of histone
deacetylation of the chromatin, causing a closed chromatin
configuration around the methylated sequences, which maintain
silencing of those genes (Lavelle, 2004). Methods for restoring
histone deacetylation might be useful in downregulation of HbF
and reduction of HbF cell concentration in tumour tissues to
normal levels. These might include reactivation of the enzymes
DNA methyl transferase (DNMT) and histone de-acetylase
(HDAC) in those erythroid cells progenitors, as inhibitors of these
enzymes are used to upregulate HbF, therapeutically
(Saunthararajah et al, 2004) for DNMT or experimentally (Witt
et al, 2003) for HDAC. Reactivation of HbF has been shown to be
mediated by certain signalling mechanisms that activate g-globin
genes via upregulation of transcription factors. These signalling
mechanisms include activation of receptor tyrosine kinase CD117
(c-kit) on the surface of erythroid progenitor cells by stem cell
factor (c-kit ligand), which has a key role in HbF reactivation in
Figure 2 Small capillary with two HbF erythroblasts.
Figure 3 Fetal haemoglobin cells, including nucleated (dark) cells, within
tumour cells of G1 TCC.
Figure 4 Fetal haemoglobin cells including nucleated (dark) cells, within
tumour cells of G2 TCC.
Figure 5 G3 TCC tumor with proliferating blood vessels (arrows) filled
with normal Hb blood cells.
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adult life (Wojda et al, 2003; Bhnu et al, 2004; Gabbianelli et al,
2010). Inhibitors of that signalling pathway, such as PD98059
(Bhnu et al, 2004), might be used to reduce the concentration
of erythroid HbF cells where they may support cancer growth.
Another approach to downregulation of HbF was shown in
leukaemia cell lines, in which the concentration of HbF decreased
to 15–5% of the control upon inhibition of the P-glycoprotein drug
efflux pump (P-gp) (Fyrberg et al, 2011), indicating a link between
P-gp and the induction of HbF.
The high incidence of blood vessels with predominant HbF
erythroid cells in non-invasive low-grade tumours of the bladder
suggests HbF as a potential prognostic marker in early stages of the
disease. The use of HbF as such a marker requires larger-scale
observation in TCC, as well as in other solid tumours. Evaluation
of bladder HbF could be facilitated by measuring its concentration
in plasma or urine, in order to avoid invasive procedures. We have
previously shown that HbF is a potential systemic blood marker
in these patients, as all 10 patients who were serologically
examined had elevated concentrations of HbF in the blood
(Wolk et al, 1988, 1991). It will be important to scrutinise the
incidence and biological behaviour of a range of tumours,
including bladder tumours, in light of the increasing use of drugs
to induce HbF therapeutically.
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